Stick-on device

Abstract

Provided is a stick-on device with improved medication absorption efficiency that can deliver medication in a state where the medication is easily released and the medication easily penetrates into the skin.　A stick-on device (100) has a medication-containing resin layer (10) having a sticking surface (10A), and a moisture holding part (20).

Description

Adhesive devices

[0001] This disclosure relates to an adhesive device, more specifically, to an adhesive device used by being attached to the skin.

[0002] Methods of administering drugs for purposes such as treating or preventing diseases, pre-procedure anesthesia, and cosmetic care include oral administration, subcutaneous injection, intramuscular injection, intravenous injection, rectal administration via suppositories, continuous administration via intravenous drip, and transdermal administration by applying to the skin. Among these, transdermal administration by applying to the skin has the advantage of being non-invasive, minimizing the burden on the patient, and ensuring continuous administration.

[0003] For example, Patent Documents 1 and 2 disclose thermal cosmetic sheets and sheet-type face packs. Patent Document 3 discloses a film for attaching to biological tissues that enhances moisture barrier properties for cosmetic and medical applications. Patent Document 4 discloses a gel sheet for packs, and Patent Document 5 discloses a patch.

[0004] Japanese Patent Publication No. 2010-53061, Japanese Patent Publication No. 2017-197269, International Publication No. 2021 / 085069, Japanese Patent Publication No. 2006-056543, Japanese Patent Publication No. 2023-070505

[0005] Conventional sheet-type or film-type transdermal patches sometimes have difficulty releasing drugs from the sheet or film. Furthermore, the drugs have difficulty penetrating the skin, resulting in challenges with drug absorption efficiency. Therefore, this disclosure aims to provide a transdermal patch that allows for easy drug release and administration in a state where the drug can easily penetrate the skin, thereby improving drug absorption efficiency.

[0006] The following is an adhesive device according to the embodiment of this disclosure that has solved the above problems: [1] An adhesive device having a drug-containing resin layer having an adhesive surface and a moisture-retaining portion.

[0007] By bringing the adhesive surface of the drug-containing resin layer into contact with the moisture-retaining portion before applying it to the skin, the moisture retained in the moisture-retaining portion can be transferred to the adhesive surface. The moisture adhering to the adhesive surface of the drug-containing resin layer adheres to the skin surface, making the skin surface covered by the drug-containing resin layer more susceptible to swelling and softening due to the moisture. This increases the adhesion of the drug-containing resin layer to the skin surface and enhances the penetration of the drug from the drug-containing resin layer into the skin.

[0008] The above-mentioned adhesive device is preferably any of the following [2] to

[24] . [2] The adhesive device according to [1], which has a laminate comprising a support having a first surface and a second surface opposite to the first surface, and the drug-containing resin layer laminated on the first surface side of the support, wherein the water content of the laminate, as measured by the Karl Fischer method in accordance with the Japanese Pharmacopoeia, is 0 ppm or more and 50,000 ppm or less by mass ratio.

[0009] The above-mentioned adhesive device has a laminate with a water content of 0 ppm to 50,000 ppm by mass ratio, as measured by the Karl Fischer method in accordance with the Japanese Pharmacopoeia, and the drug-containing resin layer constituting the laminate is hydrophobic. Therefore, when the drug-containing resin layer comes into contact with the moisture in the moisture-retaining part, the water is less likely to seep into the interior of the drug-containing resin layer and can be retained on the adhesive surface. As a result, the drug in the drug-containing resin layer is easily released into the water retained on the adhesive surface. Furthermore, since the drug contained in water in this way penetrates the skin more easily than when it is not contained in water, the adhesive device can be made to allow the drug to be easily absorbed through the skin. The above-mentioned adhesive device has both a hydrophobic drug-containing resin layer and a moisture-retaining part. As a result, by bringing the drug-containing resin layer of the adhesive device into contact with the moisture-retaining part, the above effect can be easily achieved without any additional treatment of the skin before applying the adhesive device. In addition, because water is retained on the adhesive surface when the drug-containing resin layer is in contact with the moisture-retaining part, the adhesive surface does not stick firmly to the skin, making it easier to reapply. Furthermore, after the drug contained in the water has penetrated the skin, the adhesive properties of the patch can be restored.

[0010] [3] The adhesive device according to [2], wherein when a 2 μL water droplet is dropped onto the second surface of the support in an environment of 20°C and 50% RH, the water contact angle is 90 degrees or more. [4] An adhesive device having a support having a first surface and a second surface opposite to the first surface, a laminate including a drug-containing resin layer laminated on the first surface side of the support, and a moisture-retaining portion, wherein the area A cm from the laminate ２ The increase in weight per unit area of ​​the laminated sample W2 when the laminated sample is immersed in water for 10 seconds so that the drug-containing resin layer is submerged, then removed from the water and suspended vertically for 10 seconds, and then placed horizontally with the second surface facing downwards, relative to the weight W1 of the cut laminated sample, is dW [(W2 - W1) / A]. ２ 5mg / cm or more ２ The adhesive device described in any one of the following items [1] to [3].

[0011] The above-mentioned adhesive device exhibits a weight increase of 0 mg / cm² after immersion in water compared to the weight before immersion in water. ２ 5mg / cm or more ２The amount of drug-containing resin layer is small, and the drug-containing resin layer is hydrophobic. Because the drug-containing resin layer is hydrophobic and the adhesive device has a moisture-retaining section, when the drug-containing resin layer comes into contact with the moisture in the moisture-retaining section, water is less likely to seep into the drug-containing resin layer and can be retained on the adhesive surface. This makes it easier for the drug in the drug-containing resin layer to be released into the water retained on the adhesive surface. Furthermore, since the drug contained in the water penetrates the skin more easily than when it is not contained in water, the adhesive device allows for easier absorption of the drug through the skin. The above adhesive device has both a hydrophobic drug-containing resin layer and a moisture-retaining section. Therefore, by bringing the drug-containing resin layer of the adhesive device into contact with the moisture-retaining section, the above effects can be easily achieved without any additional treatment of the skin before applying the adhesive device. Also, because water is retained on the adhesive surface when the drug-containing resin layer is in contact with the moisture-retaining section, the adhesive surface becomes less likely to stick firmly to the skin, making it easier to reapply. Furthermore, after the drug contained in the water has penetrated the skin, the adhesiveness of the adhesive surface can be restored.

[0012] [5] The increase dW is 0 mg / cm ２ 1mg / cm or more ２ The adhesive device described in [4] below. [6] The adhesive device described in any one of [1] to [5], wherein the adhesive surface of the drug-containing resin layer has a portion A having an arithmetic mean roughness Ra of 5 μm or more and 15 μm or less.

[0013] The above-described adhesive device has a drug-containing resin layer having a portion A on the adhesive surface where the arithmetic mean roughness Ra is between 5 μm and 15 μm. Since the portion A having the predetermined range of arithmetic mean roughness Ra has improved water repellency, when the adhesive surface of the drug-containing resin layer comes into contact with the moisture in the moisture-retaining portion, the water is less likely to seep into the interior of the drug-containing resin layer and can be retained on the adhesive surface. As a result, the drug released from the drug-containing resin layer can be contained in the water retained on the adhesive surface. Since the drug contained in water in this way penetrates the skin more easily than when it is not contained in water, the adhesive device can be made to allow the drug to be easily absorbed through the skin. The above-described adhesive device has both a drug-containing resin layer having the predetermined range of arithmetic mean roughness Ra and a moisture-retaining portion. As a result, by bringing the drug-containing resin layer of the adhesive device into contact with the moisture-retaining portion, the above effect can be easily achieved without any additional treatment of the skin before applying the adhesive device. In addition, by bringing the drug-containing resin layer into contact with the moisture-retaining portion, the adhesive surface becomes less likely to stick firmly to the skin, making it easier to reapply. Furthermore, the adhesiveness of the adhesive surface can be restored after the drug contained in the water has penetrated the skin. [7] The adhesive device according to [6], wherein the maximum height Rz of the portion A is 30 μm or more and 100 μm or less. [8] The adhesive device according to any one of [1] to [7], wherein the adhesive surface has a hydrophobic region and a water-permeable sheet that is peelably bonded to the adhesive surface. [9] The adhesive device according to [8], wherein the adhesive device is used by bringing the water-permeable sheet into contact with the moisture-retaining portion and wetting the water-permeable sheet.

[10] The adhesive device according to [8] or [9], wherein the water-permeable sheet is a perforated sheet or a mesh sheet.

[11] The adhesive device according to any one of [8] to

[10] , wherein the water-permeable sheet covers an area of ​​50% or more of the adhesive surface.

[12] The adhesive device according to any one of [8] to

[11] , wherein the water-permeable sheet is provided extending beyond the adhesive surface.

[13] The adhesive device according to any one of [8] to

[12] , wherein the water-permeable sheet has a tab that is folded back on the opposite side of the adhesive surface.

[14] The water-permeable sheet comprises a first water-permeable sheet and a second water-permeable sheet, the first water-permeable sheet is releasably bonded to the application surface, and the second water-permeable sheet is releasably bonded to the application surface and laminated on a surface of the first water-permeable sheet opposite to the application surface. The application device according to any one of [8] to

[13] .

[15] The application device comprises a laminate including a support having a first surface and a second surface opposite to the first surface, and the drug-containing resin layer laminated on the first surface side of the support, wherein a moisture content of the laminate measured by the Karl Fischer method in accordance with the Japanese Pharmacopoeia is 0 ppm or more and 50000 ppm or less by mass ratio. The application device according to any one of [8] to

[14] .

[16] The application device according to

[15] , wherein a water contact angle is 90 degrees or more when 2 μL of a water droplet is dropped onto the second surface of the support in an environment of 20° C. and 50% RH.

[17] The application device comprises a laminate including a support having a first surface and a second surface opposite to the first surface, and the drug-containing resin layer laminated on the first surface side of the support, wherein an area A cm from the laminate. ２ With respect to the weight W1 of a cut laminate sample, the increase dW [(W2-W1) / A] in weight W2 per unit area obtained after the following steps: immersing the laminate sample for 10 seconds such that the drug-containing resin layer is immersed in water, pulling the laminate sample out of the water and hanging it in the vertical direction for 10 seconds, then allowing the laminate sample to stand horizontally with the second surface facing downward is 0 mg / cm ２ or more and 5 mg / cm ２ or less. The application device according to any one of [8] to

[16] .

[18] The increase dW is 0 mg / cm ２ or more and 1 mg / cm ２The adhesive device according to

[17] , which is as follows:

[19] The adhesive device according to any one of [8] to

[18] , wherein the adhesive surface of the drug-containing resin layer has a portion A having an arithmetic mean roughness Ra of 5 μm or more and 15 μm or less.

[20] The adhesive device according to

[19] , wherein the maximum height Rz of the portion A is 30 μm or more and 100 μm or less.

[21] The adhesive device according to any one of [1] to

[20] , wherein the drug-containing resin layer is adhesive.

[22] The adhesive device according to any one of [1] to

[21] , wherein the moisture-retaining portion comprises a porous body that retains moisture or a fiber aggregate that retains moisture.

[23] The adhesive device according to any one of [1] to

[22] , further comprising a support laminated on the side of the drug-containing resin layer opposite to the adhesive surface, wherein water is attached to the adhesive surface of the drug-containing resin layer.

[24] The adhesive device according to

[23] , wherein, in a plan view from the adhesive surface side, the total area of ​​the portion to which water is attached is 5% or more and 100% or less of the area of ​​the adhesive surface.

[0014] The above-described patch device allows for easy drug release and penetration into the skin, thereby improving drug absorption efficiency. Furthermore, because it has both a drug-containing resin layer and a moisture-retaining layer, the above effects can be easily achieved without any additional treatment of the skin before application of the patch device. In addition, it is easy to reposition during application, and its adhesive properties can be restored after application. This makes it possible to improve the efficiency of treatment and complete pre-procedure anesthesia in a predetermined time using a simple method, thereby reducing the burden on patients and medical personnel.

[0015] It is a cross-sectional view of the application device according to one embodiment of the present disclosure. It is a plan view of the application device according to one embodiment of the present disclosure. It is a cross-sectional view taken along line III-III in FIG. 2. It is a cross-sectional view showing a modified example of FIG. 3. It is a schematic diagram showing a method for measuring the weight increase per unit area of the drug-containing resin layer before and after immersion in water. It is a plan view of the application device according to one embodiment of the present disclosure. It is a cross-sectional view taken along line VII-VII in FIG. 6. It is a cross-sectional view showing a modified example of FIG. 7. It is a plan view showing a modified example of FIG. 6. It is a cross-sectional view showing another modified example of FIG. 7. It is a cross-sectional view of the application device according to one embodiment of the present disclosure. It is a plan view of the application device shown in FIG. 11 as viewed from above. It is a cross-sectional view showing a modified example of FIG. 11. It is a cross-sectional view showing another modified example of FIG. 11. It is a cross-sectional view showing still another modified example of FIG. 11. It is a cross-sectional view of the application device shown in FIG. 11 in a folded state. It is a cross-sectional view of the application device according to one embodiment of the present disclosure. It is a cross-sectional view of the application device according to one embodiment of the present disclosure. It is a cross-sectional view of the application device according to one embodiment of the present disclosure. It is a cross-sectional view of the application device according to one embodiment of the present disclosure. It is a cross-sectional view after the drug-containing resin layer comes into contact with the moisture retention part in one embodiment of the present disclosure. It is a cross-sectional view showing a modified example of FIG. 21.

[0016] Hereinafter, the present disclosure will be described based on embodiments. However, the present disclosure is not limited by the following embodiments, and it is of course possible to implement the present disclosure with appropriate modifications within a range that conforms to the spirit of the preceding and following descriptions, all of which are included in the technical scope of the present disclosure. In each drawing, hatching, member reference numerals, and the like may be omitted for convenience; in such cases, reference shall be made to the specification and other drawings. In addition, the dimensions of various members in the drawings are prioritized to facilitate understanding of the features of the present disclosure, and therefore may differ from actual dimensions.

[0017] The application device according to the embodiment of the present disclosure is summarized in that it comprises a drug-containing resin layer having an application surface and a moisture retention part.

[0018] An adhesive device according to an embodiment of the present disclosure will be described with reference to Figures 1 to 22. Figure 1 is a cross-sectional view of an adhesive device according to one embodiment of the present disclosure. Figure 2 is a plan view of an adhesive device according to one embodiment of the present disclosure. Figure 3 is a cross-sectional view along line III-III in Figure 2. Figure 4 is a cross-sectional view showing a modified example of Figure 3. Figure 5 is a schematic diagram showing a method for measuring the weight increase per unit area of ​​a drug-containing resin layer before and after immersion in water. Figure 6 is a plan view of an adhesive device according to one embodiment of the present disclosure. Figure 7 is a cross-sectional view along line VII-VII in Figure 6. Figure 8 is a cross-sectional view showing a modified example of Figure 7. Figure 9 is a plan view showing a modified example of Figure 6, showing a configuration in which the drug-containing resin layer has a portion A in part of the total area of ​​the adhesive surface. Figure 10 is a cross-sectional view showing a modified example of Figure 7, showing a configuration in which the adhesive device further has a support laminated on the surface opposite to the adhesive surface of the drug-containing resin layer. Figure 11 is a cross-sectional view according to one embodiment of the adhesive device of the present disclosure, and Figure 12 is a plan view of the adhesive device shown in Figure 11, viewed from above. Figure 13 is a cross-sectional view of another embodiment of the adhesive device, showing a configuration in which the water-permeable sheet extends beyond the adhesive surface. Figure 14 is a cross-sectional view of yet another embodiment of the adhesive device, showing a configuration in which the water-permeable sheet has a tab that is folded back on the opposite side of the adhesive surface. Figure 15 is a cross-sectional view of yet another embodiment of the adhesive device, showing a configuration in which the water-permeable sheet includes a first water-permeable sheet and a second water-permeable sheet. Figure 16 is a cross-sectional view of the adhesive device shown in Figure 11, with the base material folded back at the planned folding point. Figure 17 is a cross-sectional view of the adhesive device that has been pre-folded along the folding line. Figure 18 is a cross-sectional view of another embodiment of the adhesive device, showing an embodiment in which a support layer is provided below the drug-containing resin layer in the adhesive device shown in Figure 11. Figure 19 is a cross-sectional view showing an embodiment in which a release sheet is further provided in the adhesive device shown in Figure 11, and Figure 20 is a cross-sectional view showing an embodiment in which a release sheet is further provided in the adhesive device shown in Figure 17. Figure 21 is a cross-sectional view of one embodiment of the present disclosure after the drug-containing resin layer has come into contact with the moisture-retaining portion, showing a state in which droplet-shaped water is attached to the adhesive surface.Fig. 22 is a cross-sectional view showing a modification of Fig. 21, and illustrates an embodiment in which layered water adheres to the application surface.

[0019] As shown in Fig. 1, the application device 100 includes a drug-containing resin layer 10 having an application surface 10A, and a moisture retaining portion 20. The drug-containing resin layer 10 has a thickness direction t, and the thickness direction t is preferably a direction perpendicular to the application surface 10A.

[0020] The drug-containing resin layer 10 contains at least a drug and a resin. In the drug-containing resin layer 10, the drug is preferably dispersed in the resin. The drug may be arranged uniformly or non-uniformly in the resin. For example, the drug may be arranged in the resin such that portions with a high drug concentration and portions with a low drug concentration are formed.

[0021] Examples of the drug include low-molecular-weight compounds, high-molecular-weight compounds such as peptides, proteins and oligonucleotides, antibody drugs, and nucleic acid drugs. The drug compound preferably has an ionizing group. Accordingly, as will be described later, when the drug-containing resin layer 10 is brought into contact with the moisture retaining portion 20 to apply water to the application surface 10A of the drug-containing resin layer 10 and the device is applied to the skin, release of the drug from the drug-containing resin layer 10 is promoted, and the drug can be administered in a state that allows it to easily penetrate into the skin. Examples of the ionizing group include an amino group, a carboxy group, a sulfonic acid group, and a phosphoric acid group, and these ionizing groups may exist in the form of a pharmaceutically acceptable salt. It is also preferable that the drug compound has an aromatic group, which facilitates allowing the drug to exist at a high concentration in the resin. The aromatic group is more preferably an aromatic hydrocarbon group.

[0022] The drug contained in the drug-containing resin layer 10 is preferably a pharmaceutical product. Examples of such drugs include anti-inflammatory and analgesic agents such as acetaminophen, phenacetin, mefenamic acid, diclofenac sodium, flufenamic acid, aspirin, sodium salicylate, methyl salicylate, glycol salicylate, aminopyrine, alclofenac, ibuprofen, naproxen, flurbiprofen, ketoprofen, amfenac sodium, mepirizole, indomethacin, piroxicam, and felbinac; steroidal anti-inflammatory agents such as hydrocortisone, triamcinolone, dexamethasone, and prednisolone; and salts. Vasodilators such as diltiazem acid, pentaerythritol tetranitrate, isosorbide dinitrate, tarajipyr, nicorandil, nitroglycerin, preniramine lactate, morcidomin, amyl nitrite, trazoline hydrochloride, and nifedipine; antiarrhythmic agents such as procainamide hydrochloride, lidocaine hydrochloride, propranolol hydrochloride, alprenolol hydrochloride, atenolol, nadolol, metoprolol tartrate, ajmaline, disopyramide, and mexiletine hydrochloride; ecalazine hydrochloride, indapamide, clonidine hydrochloride, bnitrolol hydrochloride, labetalol hydrochloride, and captopramide. Antihypertensive agents such as ryl, guanabenz acetate, mebutamate, and betanidine sulfate; antihypertensive agents such as carbetapentane citrate, cloperastin, oxerazine tannate, cloptinol hydrochloride, clofedanol hydrochloride, noscapine hydrochloride, ephedrine hydrochloride, isoproterenol hydrochloride, chloriprenaline hydrochloride, methoxyphenamine hydrochloride, procaterol hydrochloride, tulobuterol hydrochloride, clenputerol hydrochloride, and ketotifen fumarate; cyclophosphamide, fluorouracil, degafur, mitomycin C, procarbazine hydrochloride, and doxif Antineoplastic agents such as rulizine and ranimustine; local anesthetics such as ethyl aminobenzoate, tetracaine hydrochloride, brocaine hydrochloride, dibucaine hydrochloride, oxybuprocaine hydrochloride, and propitocaine hydrochloride; hormonal agents such as propylthiouracil, thiamazole, meteronone acetate, estradiol, estriol, and progesterone; antihistamines such as diphenhydramine hydrochloride, chlorpheniramine maleate, promethazine, diproheptadine hydrochloride, and diphenylpyraline hydrochloride; anticoagulants such as warfarin potassium and ticlopidine hydrochloride;Antispasmodics such as methylatropine bromide and scopolamine; general anesthetics such as thiopental sodium and pentobarbital sodium; hypnotics and analgesics such as bromwarenylurea, amobarbital, and phenobarbital; antiepileptics such as phenytoin sodium; stimulants and aphrodisiacs such as methamphetamine hydrochloride; sedatives such as difendol hydrochloride and betahistine mesylate; chlorpromazine hydrochloride, thioridazine, meprobamate, imipramine hydrochloride, chlordiazepoxide, diazepam, risperidone, and paliperidone. Psychotropic agents such as olanzapine, aripiprazole, paroxetine, and duloxetine; skeletal muscle relaxants such as succinylcholine and eperisone hydrochloride; autonomic nervous system agents such as neostigmine bromide and bethanechol chloride; antiparkinsonian agents such as amantadine hydrochloride, rotigotine, and ropinirole; anti-Alzheimer's disease drugs such as donepezil, galantamine, memantine, and rivastigmine; diuretics such as hydroflumethiazide, isosorbide, and furosemide; vasoconstrictors such as phenylephrine hydrochloride; roberine bromide, dimo Respiratory stimulants such as ruhoramine and naloxone hydrochloride; peptic ulcer treatments such as glycopyrronium bromide, proglumide, cetraxate hydrochloride, cimetidine, and spizoflon; cholagogues such as ursodeoxycholic acid and osalmid; urogenital and anal preparations such as hexamine, spartin, dinoprost, ritodrine hydrochloride, oxybutynin, tolterodine, solifenacin, and dalifenacin; parasitic skin disease treatments such as salicylic acid, cyclopiroxolamine, and coloconazole hydrochloride; emollients such as urea; calcitriol Vitamin preparations such as thiamine hydrochloride, riboflavin sodium phosphate, pyridoxine hydrochloride, nicotinamide, panthenol, and ascorbic acid; inorganic preparations such as calcium chloride, potassium iodide, and sodium iodide; hemostatic agents such as ethanesylates; liver disease agents such as thiopronin; habitual poisoning agents such as cyanamide; gout treatment agents such as colchicine, probenecid, and sulfinpyrazone; antidiabetic agents such as tolbutamide, chlorpropamide, glimidine sodium, glypsol, buformin hydrochloride, and insulin;Examples include antibiotics such as benzylpenicillin potassium, propicillin potassium, cloxacillin sodium, ampicillin sodium, bacampyricin hydrochloride, carbenicillin sodium, cephalolidine, cefoxitin sodium, erythromycin, chloramphenicol, tetracycline, kanamycin sulfate, and cycloserine; chemocytogenic agents such as isocyanides, pyrazinamide, and ethionamide; and narcotics such as morphine hydrochloride, codeine phosphate, cocaine hydrochloride, pethidine hydrochloride, and fentanyl citrate.

[0023] Examples of resins that form the drug-containing resin layer 10 include fluorine-based resins such as polytetrafluoroethylene (PTFE), acrylic resins such as octyl acrylate copolymers, silicone resins, polyester resins, styrene-based thermoplastic elastomers such as styrene-isoprene-styrene block copolymers, vinyl chloride resins, polyolefin resins, acrylic acid copolymers, polyethylene glycol, vinyl polymers such as polyvinyl alcohol and polyvinylpyrrolidone, and cellulose derivatives.

[0024] The drug-containing resin layer 10 preferably has adhesive properties. This makes it easier to attach and hold the adhesive surface 10A to the skin.

[0025] For the drug-containing resin layer 10 to be adhesive, it is preferable that the resin contained in the drug-containing resin layer 10 is an elastomer resin. This makes the drug-containing resin layer 10 more easily deformable along the skin, thereby improving the adhesion and conformability to the skin when the adhesive surface 10A is applied to the skin.

[0026] The drug-containing resin layer 10 may contain a tackifier. Known tackifiers can be used.

[0027] The drug-containing resin layer 10 may contain additives such as plasticizers, drug solvents, permeation enhancers, crystal precipitation inhibitors, excipients, antioxidants, fragrances, colorants, etc.

[0028] The thickness of the drug-containing resin layer 10, i.e., the length t in the thickness direction, is preferably 0.01 mm or more, more preferably 0.05 mm or more, preferably 2.0 mm or less, more preferably 1.5 mm or less, and even more preferably 1.2 mm or less.

[0029] The shape of the adhesive surface 10A is not particularly limited, but examples include squares, rectangles, polygons, rounded polygons, circles, ellipses, dumbbell shapes, irregular shapes, etc.

[0030] The dimensions of the adhesive surface 10A may, for example, have a longitudinal length of 5 mm or more, 10 mm or more, 15 mm or more, or 140 mm or less, 100 mm or less, or 70 mm or less, and a width perpendicular to the longitudinal direction may be 2 mm or more, 5 mm or more, 10 mm or more, or 100 mm or less, 80 mm or less, or 60 mm or less. The length and width may be the same if the shape of the adhesive surface 10A is square or circular, etc.

[0031] The moisture-retaining section 20 contains at least moisture. Preferably, the moisture contains water such as tap water, purified water, distilled water, sterile purified water, or water for injection. In addition to water, the moisture may also contain additives such as sodium chloride, ethanol, or glycerin. Examples of substances containing sodium chloride in addition to water include saline solution and physiological saline solution, examples of substances containing ethanol in addition to water include disinfectant solutions and antiseptic solutions, and examples of substances containing glycerin in addition to water include cosmetics. In this specification, "water" may refer to tap water, purified water, distilled water, sterile purified water, or water for injection, or it may refer to water to which the above-mentioned additives have been added.

[0032] By bringing the adhesive surface 10A of the drug-containing resin layer 10 into contact with the moisture-retaining portion 20 before applying it to the skin, the moisture retained in the moisture-retaining portion 20 can be transferred to the adhesive surface 10A. The moisture adhering to the adhesive surface 10A of the drug-containing resin layer 10 adheres to the skin surface, making the skin surface covered by the drug-containing resin layer 10 more susceptible to swelling and softening due to the moisture. This increases the adhesion of the drug-containing resin layer 10 to the skin surface and enhances the penetration of the drug from the drug-containing resin layer 10 into the skin.

[0033] The moisture-retaining section 20 may contain only moisture. That is, the moisture-retaining section 20, which is configured to be able to seal moisture, may contain liquid moisture. By releasing the seal of the moisture-retaining section 20 and immersing the adhesive surface 10A in liquid moisture, water can be applied to the adhesive surface 10A.

[0034] Alternatively, the moisture-retaining portion 20 may have a configuration in which a moisture-retaining member retains moisture. In this case, it is preferable that the moisture-retaining portion 20 includes a porous body in which moisture is retained, or a fiber aggregate in which moisture is retained.

[0035] The porous material preferably has voids inside, and these voids are in communication with the outside of the porous material. For example, the porous material preferably contains air bubbles, and preferably has continuous air bubbles where the air bubbles are connected. The porous material preferably is elastically deformable, and a sponge is a suitable example of such a porous material, and the porous material is preferably composed of a resin. Examples of resins that constitute the porous material include polyurethane resins, fluororesins such as PTFE, PFA, and ETFE, polyolefin resins such as polyethylene and polypropylene, polyester resins such as polyethylene terephthalate and polybutylene terephthalate, silicone resins such as polydimethylsiloxane, polyamide resins such as nylon, and cellulose derivatives such as hydroxyethylcellulose and hydroxypropylcellulose.

[0036] Examples of fiber aggregates include nonwoven fabrics, woven fabrics, knitted fabrics, and other fabric materials, as well as fiber bundles. Fiber aggregates may also be felt or tow (fiber bundles). Fibers included in the fiber aggregates include natural fibers such as cotton, linen, and silk; regenerated fibers such as rayon; semi-synthetic fibers such as acetate; and synthetic fibers formed from polyester (e.g., PET), polyolefins (e.g., polypropylene, polyethylene), polyurethane, polyamide (e.g., nylon), acrylic, melamine, etc. It is preferable that the surface of the synthetic fibers is hydrophilized with a surfactant or the like. The basis weight of the fiber aggregate is, for example, 200 g / m². ２ The above is preferable, 400 g / m ２ The above is more preferable, and also 5000 g / m ２The following is preferable: 2500 g / m² ２ The following are preferable.

[0037] The thickness of the moisture-retaining portion 20 is preferably 1 mm or more, more preferably 2 mm or more, preferably 10 mm or less, and more preferably 8 mm or less.

[0038] The size of the moisture-retaining portion 20 is preferably such that the entire adhesive surface 10A can come into contact with the moisture-retaining portion 20.

[0039] As shown in Figures 2 to 4, the adhesive device 100 preferably has a laminate 11 comprising a support 30 having a first surface 30A and a second surface 30B opposite to the first surface 30A, and a drug-containing resin layer 10 laminated on the first surface 30A side of the support 30. That is, it is preferable that the support 30 is laminated on the surface 10B of the drug-containing resin layer 10 opposite to the adhesive surface 10A to form the laminate 11.

[0040] The support 30 and the drug-containing resin layer 10 can be laminated using a known method.

[0041] It is preferable that the thickness direction of the laminate 11 is the same as the thickness direction t of the drug-containing resin layer 10.

[0042] The support 30 is not particularly limited and general-purpose materials can be used. Examples include stretchable or non-stretchable woven or nonwoven fabrics such as polyethylene, polypropylene, and polyester; films such as polyethylene, polypropylene, ethylene vinyl acetate copolymer, vinyl chloride, and polyurethane; or foamed supports such as polyethylene and polyurethane. These may be used individually or in combination of multiple types. Furthermore, to prevent the accumulation of static electricity on the support and to ensure good anchoring with the drug-containing resin layer 10, a nonwoven or woven fabric containing an antistatic agent can be used. The support 30 may also be subjected to a release process. Examples of release processes include applying a silicone resin to create a silicone resin layer (silicone processing).

[0043] The shape and size of the support 30 can be the same as those of the drug-containing resin layer 10.

[0044] The thickness of the support 30 is preferably 0.01 mm or more, more preferably 0.02 mm or more, preferably 2.0 mm or less, more preferably 1.5 mm or less, and even more preferably 1.2 mm or less.

[0045] In one embodiment of this disclosure, the water content of the laminate 11, as measured by the Karl Fischer method in accordance with the Japanese Pharmacopoeia, is preferably 0 ppm or more and 50,000 ppm or less by mass. The water content of the laminate 11 is more preferably 40,000 ppm or less, even more preferably 30,000 ppm or less, and may be 10,000 ppm or less, 5,000 ppm or less, or 1,000 ppm or less. As long as the upper limit of the water content of the laminate 11 is within the above range, the drug-containing resin layer 10 constituting the laminate 11 can be hydrophobic.

[0046] Thus, because the drug-containing resin layer 10 is hydrophobic and the adhesive device 100 has a moisture-retaining portion 20, when the drug-containing resin layer 10 comes into contact with the moisture in the moisture-retaining portion 20, water is less likely to seep into the interior of the drug-containing resin layer 10 and can be retained on the adhesive surface 10A. As a result, the drug in the drug-containing resin layer 10 is easily released into the water retained on the adhesive surface 10A. Furthermore, since the drug contained in water in this way penetrates the skin more easily than when it is not contained in water, the adhesive device 100 can be made in which the drug is easily absorbed through the skin.

[0047] Preferably, the adhesive device 100 has both a hydrophobic drug-containing resin layer 10 and a moisture-retaining portion 20. This allows the above effects to be easily achieved without any additional treatment to the skin before applying the adhesive device 100, by bringing the drug-containing resin layer 10 of the adhesive device 100 into contact with the moisture-retaining portion 20. Furthermore, because water is retained on the adhesive surface 10A by bringing the drug-containing resin layer 10 into contact with the moisture-retaining portion 20, the adhesive surface 10A becomes less likely to stick firmly to the skin, making it easier to reapply. In addition, the adhesiveness of the adhesive surface 10A can be restored after the drug-containing water has penetrated the skin. This makes it possible to provide an adhesive device 100 that can be easily placed in the desired position and has improved drug absorption efficiency.

[0048] The water content of the laminate 11 can be measured by cutting a sample of a predetermined size from the laminate 11 and using the Karl Fischer method described in the Japanese Pharmacopoeia, with tetrahydrofuran as the solvent for sample dissolution and methanol as the solvent for polymer reprecipitation. First, the amount of water contained in the sample solution is analyzed, and then the amount of water contained in the sample can be calculated by subtracting the amount of water contained in the separately analyzed tetrahydrofuran and methanol. Volumetric titration is preferred as the measurement method. As a water meter, for example, the Karl Fischer moisture meter MKV-210 manufactured by Kyoto Electronics Manufacturing Co., Ltd. can be used. A sample of a predetermined size can be, for example, 30 mm x 30 mm.

[0049] When a 2 μL droplet of water is dropped onto the second surface 30B of the support 30 in an environment of 20°C and 50% RH, the water contact angle is preferably 90 degrees or more. More preferably, the water contact angle of the second surface 30B of the support 30 is 95 degrees or more, and even more preferably 100 degrees or more. The upper limit of the water contact angle of the second surface 30B of the support 30 is not particularly limited, but for example, it may be 160 degrees or less, 150 degrees or less, or 120 degrees or less. This makes it possible to increase the hydrophobicity of the second surface 30B of the support 30 on the side that is exposed to the outside when the adhesive surface 10A of the laminate 11 is attached to the skin, thereby making the adhesive device 100 less prone to getting wet and providing a good user experience. Furthermore, it becomes possible to reduce the influence of the support 30 when measuring the water content of the laminate 11.

[0050] The water contact angle can be measured in an environment of 20°C and 50% RH using a contact angle measuring instrument such as the Mobile Drop DSA series manufactured by KRUSS. Distilled water is dropped onto the second surface 30B from the microsyringe of the contact angle measuring instrument, and the angle between the second surface 30B and the water droplet is read one minute after dropping. The angle can be read by analyzing images captured by a camera such as a high-resolution CCD camera using analysis software. Alternatively, the water contact angle may be measured in accordance with JIS R 3257:1999, in which case the amount of water droplet may be 1 μL to 4 μL.

[0051] In one embodiment of the present disclosure, the adhesive device 100 has a laminate 11 comprising a support 30 having a first surface 30A and a second surface 30B opposite to the first surface 30A, and a drug-containing resin layer 10 laminated on the first surface 30A side of the support 30, with an area A cm² from the laminate 11. ２ The increase in weight W2 per unit area dW of the laminated sample 11S per unit area when the laminated sample 11S is immersed in water H for 10 seconds so that the drug-containing resin layer 10 is submerged, then lifted out of the water H and suspended vertically for 10 seconds, and then placed horizontally with the second surface 30B facing downwards, is 0 mg / cm². ２ 5mg / cm or more ２ The following is preferable. The increase dW is expressed by the formula [(W2 - W1) / A]. That is, the increase dW is the value obtained by subtracting the weight W1 (mg) before immersion from the weight W2 (mg) of the drug-containing resin layer 10 after immersion in water H, over the area A (cm²) of the laminate sample 11S. ２ It can be obtained by dividing by ).

[0052] Figure 5 is a schematic diagram showing an example of a method for measuring dW. The laminate sample 11S cut from the laminate 11 is preferably immersed in water H with the first surface 30A of the support 30 facing downwards, that is, with the adhesive surface 10A of the drug-containing resin layer 10 facing downwards. At this time, it is preferable that the support 30 is not immersed in water H, and at least the second surface 30B of the support 30 is not immersed in water H. Water H is preferably ordinary water, purified water, or distilled water, and more preferably distilled water. When suspending the laminate sample 11S vertically, it is preferable to use a tool that can hold the laminate sample 11S vertically with the contact area with the laminate sample 11S as small as possible, such as precision tweezers. This makes it possible to suppress the effect of the increase in dW caused by holding the laminate sample 11S with a tool.

[0053] The increase in dW is a value that indicates how easily the drug-containing resin layer 10 absorbs water, and is an indicator of the hydrophobicity of the drug-containing resin layer 10. The drug-containing resin layer 10 has an increase in dW of 0 mg / cm³. ２ 5mg / cm or more ２It is preferable that the material is small and hydrophobic. Thus, because the drug-containing resin layer 10 is hydrophobic and the adhesive device 100 has a moisture-retaining portion 20, when the drug-containing resin layer 10 comes into contact with the moisture in the moisture-retaining portion 20, water is less likely to seep into the interior of the drug-containing resin layer 10 and can be retained on the adhesive surface 10A. As a result, the drug in the drug-containing resin layer 10 is easily released into the water retained on the adhesive surface 10A. Furthermore, since the drug contained in water in this way penetrates the skin more easily than when it is not contained in water, the adhesive device 100 can be made in which the drug is easily absorbed through the skin.

[0054] By having both a drug-containing resin layer 10 and a moisture-retaining portion 20, which have the above-mentioned hydrophobicity indicators, the above-mentioned effects can be easily achieved without any additional treatment to the skin before applying the adhesive device 100 by bringing the drug-containing resin layer 10 of the adhesive device 100 into contact with the moisture-retaining portion 20. Furthermore, because water is retained on the adhesive surface 10A by bringing the drug-containing resin layer 10 into contact with the moisture-retaining portion 20, the adhesive surface 10A becomes less likely to stick firmly to the skin, making it easier to reapply. In addition, the adhesiveness of the adhesive surface 10A can be restored after the drug-containing water has penetrated the skin.

[0055] The increase in weight per unit area dW of the drug-containing resin layer 10 before and after immersion in water is 0 mg / cm². ２ 1mg / cm or more ２ The following is more preferable: Increased dW is 0.8 mg / cm³. ２ The following is even more preferable: 0.5 mg / cm ２ The following is even more preferable. If the increase in dW is within the above range, the hydrophobicity of the drug-containing resin layer 10 can be further increased, and when the drug-containing resin layer 10 is brought into contact with the moisture-retaining portion 20, the moisture in the moisture-retaining portion 20 does not seep into the drug-containing resin layer 10, making it easier to retain water on the adhesive surface 10A. As a result, the drug in the drug-containing resin layer 10 is more easily released into the water retained on the adhesive surface 10A, making it possible to create an adhesive device 100 with improved drug absorption efficiency.

[0056] The increase in weight per unit area dW of the drug-containing resin layer 10 before and after immersion in water is 0.01 mg / cm². ２ It is preferable that the above conditions are met. If the increase in dW is within the above range, the drug-containing resin layer 10 can contain a certain amount of water. As a result, a certain amount of water is maintained on the surface of the drug-containing resin layer 10, and the drug-containing water maintained on the surface of the drug-containing resin layer 10 penetrates into the skin, thereby improving the drug absorption efficiency of the patch device 100.

[0057] In one embodiment of the present disclosure, as shown in Figures 6 to 8, the adhesive surface 10A of the drug-containing resin layer 10 is a portion A (P) having an arithmetic mean roughness Ra of 5 μm or more and 15 μm or less. Ａ It is preferable that it has part A (P Ａ The arithmetic mean roughness Ra of part A (P) is preferably 5 μm or more, more preferably 6 μm or more, even more preferably 7 μm or more, and also preferably 14 μm or less, more preferably 13 μm or less, and even more preferably 12 μm or less. Ａ If the arithmetic mean roughness Ra of ) is within the above range, then part A (P Ａ Because the water repellency is improved, when the adhesive surface 10A of the drug-containing resin layer 10 comes into contact with the moisture in the moisture-retaining part 20, the water is less likely to seep into the interior of the drug-containing resin layer 10 and can be retained on the adhesive surface 10A. As a result, the drug released from the drug-containing resin layer 10 can be contained in the water retained on the adhesive surface 10A. Drugs contained in water in this way penetrate the skin more easily than drugs not contained in water, thus making the adhesive device 100 more easily absorbed by the skin.

[0058] Part A(P Ａ By forming part A (P Ａ This makes it easier to improve the water repellency of the resin. Examples of hydrophobic resins include fluororesins, acrylic resins, silicone resins, polyester resins, and styrene-based thermoplastic elastomers.

[0059] The adhesive device 100 has a portion A (P) having an arithmetic mean roughness Ra within the predetermined range. ＡIt is preferable to have both a drug-containing resin layer 10 having a moisture-retaining portion 20. This allows the above effect to be easily achieved without any additional treatment to the skin before applying the adhesive device 100 by bringing the drug-containing resin layer 10 of the adhesive device 100 into contact with the moisture-retaining portion 20.

[0060] Furthermore, by bringing the drug-containing resin layer 10 into contact with the moisture-retaining portion 20, water is more easily retained on the adhesive surface 10A, making it less likely for the adhesive surface 10A to adhere firmly to the skin, thus making it easier to reapply. In addition, the adhesive properties of the adhesive surface 10A can be restored after the drug contained in the water has penetrated the skin. As a result, an adhesive device 100 can be easily placed in the desired position and has improved drug absorption efficiency.

[0061] Part A(P Ａ The maximum height Rz of part A (P) is preferably 30 μm or more and 100 μm or less. Ａ The maximum height Rz of part A (P) is more preferably 40 μm or more, even more preferably 50 μm or more, even more preferably 90 μm or less, and even more preferably 80 μm or less. Ａ By having the maximum height Rz of the ) be within the above range, when the adhesive surface 10A of the drug-containing resin layer 10 comes into contact with the moisture in the moisture-retaining part 20, the water is less likely to seep into the interior of the drug-containing resin layer 10 and is more easily retained on the adhesive surface 10A.

[0062] The arithmetic mean roughness Ra and maximum height Rz can be measured in accordance with JIS B 0601 (2001), for example, using a laser microscope such as the VK-X3000 series manufactured by Keyence Corporation. The length scanned in a single measurement, i.e., the reference length, may be, for example, 2500 μm.

[0063] The above measurement is performed at five locations on a 40 mm square sample of the adhesive surface 10A. If the average value of the five measured values ​​of the arithmetic mean roughness Ra at the five locations is 5 μm or more and 15 μm or less, the 40 mm square portion is designated as part A (P Ａ ) can be done. If a 40 mm square sample cannot be taken from the adhesive surface 10A, the sample size may be 20 mm square, 10 mm square, 5 mm square, etc.

[0064] The drug-containing resin layer 10 can be formed by applying the material for the drug-containing resin layer 10 using known methods such as roll coating, die coating, gravure coating, knife coating, bar coating, or spray coating.

[0065] Methods for achieving the above-mentioned arithmetic mean roughness Ra and maximum height Rz include, for example, adjusting the surface shape of the rolls and dies, adjusting the gauge of the wire bars used for bar coating, adjusting the mist size during spray coating, adjusting the viscosity of the resin, adjusting the drying conditions, transferring the embossing roll, and performing blasting.

[0066] For the entire surface area of ​​the adhesive surface 10A of the drug-containing resin layer 10, a portion A (P Ａ The area occupied by part A (P) is preferably 50% or more and 100% or less. Ａ The area occupied by part A (P Ａ The area occupied by the above-mentioned area makes it possible to improve the drug release and absorption efficiency.

[0067] On the adhesive surface 10A, portion A (P Ａ The portion other than ) has an arithmetic mean roughness Ra of less than 5 μm (P Ｂ ) may also be part B(P Ｂ The arithmetic mean roughness Ra of part B (P) is preferably less than 5 μm, more preferably 4 μm or less, and even more preferably 3 μm or less. Ｂ The lower limit of the arithmetic mean roughness Ra of the adhesive surface 10A is not particularly limited, but may be, for example, 0.01 μm or more, or 0.1 μm or more. Ｂ ) has part B (P Ｂ This allows the adhesive device 100 to adhere more easily to the skin, enabling stable attachment of the device to the skin.

[0068] As shown in Figure 9, in a plan view from the adhesive surface 10A side, portion B (P Ｂ ) is provided on the peripheral edge of the adhesive surface 10A, and part B (PＢ ) is part A (P Ａ It is preferable that it surrounds part B (P Ｂ ) enhances adhesion to the skin, so part A (P Ａ This prevents the water held in the container from dripping.

[0069] The arithmetic mean roughness Ra of the surface 30B opposite to the surface 30A on which the drug-containing resin layer 10 of the support 30 is laminated is given by part A (P Ａ It is preferable that the arithmetic mean roughness Ra of surface B is greater than that of surface B. The drug-containing resin layer 10 can be attached to the skin by grasping the surface 30B of the support 30 opposite to the surface 30A on which the drug-containing resin layer 10 is laminated with a finger. If the arithmetic mean roughness Ra of surface B is relatively large, it is possible to create an attachment device 100 that is easy to attach without the finger slipping.

[0070] Alternatively, the arithmetic mean roughness Ra of the surface 30B opposite to the surface 30A on which the drug-containing resin layer 10 of the support 30 is laminated is the portion A (P Ａ The surface 30B of the support 30 opposite to the surface 30A on which the drug-containing resin layer 10 is laminated is the surface that becomes the outside after the drug-containing resin layer 10 is attached to the skin. Therefore, by being relatively smooth, discomfort caused by the attachment of the drug-containing resin layer 10 is reduced, and snagging is reduced, preventing peeling.

[0071] As an example of a configuration in which the adhesive surface 10A of the drug-containing resin layer 10 is brought into contact with the moisture-retaining portion 20, as shown in Figures 2, 3, and 10, the adhesive device 100 further has a base material 40, and the drug-containing resin layer 10 and the moisture-retaining portion 20 are provided on the base material 40. The adhesive device 100 can, for example, peel the drug-containing resin layer 10 from the base material 40 and attach it to the skin. The drug-containing resin layer 10 and the moisture-retaining portion 20 are provided on the base material 40, and it is preferable to fold the base material 40 at the planned folding portion 44 so that the adhesive surface 10A of the drug-containing resin layer 10 and the moisture-retaining portion 20 face each other. Alternatively, a laminate 11 including a support 30 and the drug-containing resin layer 10 and the moisture-retaining portion 20 may be provided on the base material 40, and the base material 40 may be folded at the planned folding portion 44 so that the adhesive surface 10A of the drug-containing resin layer 10 and the moisture-retaining portion 20 face each other. In this case, it is preferable that the laminate 11 is placed on the substrate 40 such that the second surface 30B of the support 30, which is opposite to the adhesive surface 10A of the drug-containing resin layer 10, faces the substrate 40.

[0072] The base material 40 has a first surface 40A and a second surface 40B, and it is preferable that the drug-containing resin layer 10 and the moisture-retaining portion 20 are provided on the first surface 40A of the base material 40. Both the first surface 40A and the second surface 40B are the main surfaces of the base material 40, with the first surface 40A being the upper surface of the base material 40 and the second surface 40B being the lower surface of the base material 40. It is preferable that the base material 40 is in the form of a sheet.

[0073] The adhesive device 100, which has a base material 40, has a planar direction in which the base material 40 extends and a thickness direction perpendicular to the planar direction. An upper side and a lower side are defined with respect to the thickness direction; the upper side is the side that faces the skin (epithelial tissue) when the adhesive device 100 is placed on the skin and used, and the lower side is the opposite side.

[0074] Preferably, the drug-containing resin layer 10 and the moisture-retaining portion 20 are provided in different regions of the first surface 40A of the base material 40. For example, the first surface 40A of the base material 40 is divided into a first region 41 and a second region 42, the drug-containing resin layer 10 is provided in the first region 41, and the moisture-retaining portion 20 is provided in the second region 42.

[0075] As shown in Figures 3 and 10, when the adhesive device 100 has a support 30, it is preferable that the second surface 30B of the support 30 is positioned to face the first region 41, and the moisture-retaining portion 20 is held in the second region 42. With this configuration, for example, by folding the base material 40 at the planned folding portion 44, the adhesive surface 10A of the drug-containing resin layer 10 can be brought into contact with the moisture-retaining portion 20. When the base material 40 is folded at the planned folding portion 44, the first region 41 and the second region 42 may be provided with the planned folding portion 44 as the boundary.

[0076] The release sheet 60 may be positioned to cover the adhesive surface 10 of the drug-containing resin layer 10 and the moisture-retaining portion 20. Preferably, the release sheet 60 is removably bonded to the base material 40, which will be described later. This protects the drug-containing resin layer 10 and prevents the adhesive surface 10A from coming into contact with the moisture in the moisture-retaining portion 20 or sticking to other components before use of the adhesive device 100. It also prevents moisture from leaking from the moisture-retaining portion 20 before use of the adhesive device 100. The release sheet 60 can be removed when using the adhesive device 100.

[0077] Alternatively, as shown in Figure 4, the adhesive surface 10A of the drug-containing resin layer 10 and the moisture-retaining portion 20 are arranged to face each other via a release sheet 60, and the adhesive surface 10A of the drug-containing resin layer 10 can be brought into contact with the moisture-retaining portion 20 by removing the release sheet 60, for example.

[0078] There are no particular restrictions on the release sheet 60, and it can be appropriately selected according to the purpose. For example, glassine paper, polyolefins such as polyethylene and polypropylene, polyesters such as polyethylene terephthalate, resin films such as polystyrene, aluminum films, foamed polyethylene films or foamed polypropylene films, or laminates of two or more of the above can be used. Furthermore, the release sheet 60 can also be treated with silicone processing, fluororesin processing, embossing, hydrophilic processing, hydrophobic processing, etc.

[0079] It is preferable that the moisture-retaining portion 20 is fixed to the base material 40. This allows the moisture-retaining portion 20 to be removed along with the base material 40 after the laminate 11 has been attached to the skin.

[0080] It is preferable that a recess 46 is provided on the first surface 40A of the base material 40, and that the moisture-retaining portion 20 is placed in the recess 46. By placing the moisture-retaining portion 20 in the recess 46 of the first surface 40A of the base material 40, moisture can be stably retained in the moisture-retaining portion 20. If the moisture-retaining portion 20 is a porous material or a fiber aggregate in which moisture is retained, it is prevented that the moisture-retaining portion 20 is inadvertently pressed before use of the adhesive device 100, and moisture is stably retained in the porous material or fiber aggregate.

[0081] The recess 46 is formed by recessing the first surface 40A of the base material 40. Preferably, the recess 46 is provided in the second region 42 of the base material 40. Preferably, the recess 46 in which the moisture-retaining portion 20 is placed is formed only in the second region 42 of the base material 40.

[0082] There are no particular restrictions on the materials that constitute the base material 40, and they can be appropriately selected according to the purpose. Examples include polyolefins such as polyethylene and polypropylene, polyesters such as polyethylene terephthalate, polyamides such as nylon 6, polycarbonate, polyvinyl alcohol, ethylene-vinyl alcohol copolymer, polyvinyl chloride, polyvinylidene chloride, polystyrene, cellulose, resin films such as acrylic resin; aluminum foil or aluminum film; foamed resin films such as foamed polyethylene film and foamed polypropylene film; and paper such as glassine paper. These may be used individually or in combination of multiple types.

[0083] The thickness of the base material 40 is preferably 0.05 mm or more, more preferably 0.1 mm or more, preferably 3.0 mm or less, more preferably 2.0 mm or less, and even more preferably 1.0 mm or less.

[0084] The shape of the base material 40 is not particularly limited, but examples include squares, rectangles, polygons, rounded polygons, circles, ellipses, dumbbell shapes, irregular shapes, etc.

[0085] The size of the base material 40 is not particularly limited as long as the drug-containing resin layer 10 and the moisture-retaining portion 20 can be arranged on the first surface 40A.

[0086] Preferably, the support 30 is detachably attached to the base material 40. This allows the base material 40 to be grasped and the laminate 11, including the support 30 and the drug-containing resin layer 10, to be attached to the skin, after which the base material 40 can be peeled off and removed from the support 30, making it possible to attach the laminate to the skin without touching the drug-containing resin layer 10. Furthermore, even if the drug-containing resin layer 10 is adhesive, it is possible to prevent the drug-containing resin layer 10 from sticking to areas other than the target skin, and it can be easily attached to the desired position.

[0087] The adhesive device 100 can, for example, peel off the drug-containing resin layer 10 from the base material 40 and attach it to the skin. In this case, as shown in Figures 3, 10, and 18, it is preferable that a support 30 is provided on the surface 10B of the drug-containing resin layer 10 that is on the base material 40 side, i.e., the lower side, and that the support 30 is detachably attached to the base material 40. Figures 3, 10, and 18 show cross-sectional views of other embodiments of the adhesive device 100, and Figure 11 shows an embodiment in which the support 30 is provided on the surface 10B that is the lower side of the drug-containing resin layer 10. The support 30 may be treated integrally with the drug-containing resin layer 10 as a laminate 11. By peeling the drug-containing resin layer 10 together with the support 30 from the base material 40, the drug-containing resin layer 10 can be attached to the skin.

[0088] When the support 30 is detachably attached to the base material 40, it is preferable that an adhesive portion is provided on the first surface 40A of the base material 40 overlapping with the support 30. This allows the support 30 to be detachably attached to the base material 40. In this case, the adhesive portion does not need to be provided in the area of ​​the first surface 40A of the base material 40 where the support 30 is not placed, thereby making it easier to peel the support 30 from the base material 40. The adhesive portion may be provided over the entire area of ​​the first surface 40A of the base material 40 where the support 30 is placed, or it may be provided only in a part of it. From the viewpoint of making it easier to peel the support 30 from the base material 40, it is preferable that, in a plan view of the attachment device 100, at least a part of the outer edge of the adhesive portion is located inward from the outer edge of the support 30, and it is more preferable that the entire outer edge of the adhesive portion is located inward from the outer edge of the support 30.

[0089] The adhesive device 100 may be used by attaching the drug-containing resin layer 10 to the skin together with the base material 40. In this case, it is preferable that an adhesive portion is provided around the drug-containing resin layer 10 on the first surface 40A of the base material 40. This allows the base material 40 to adhere to the skin so as to surround the drug-containing resin layer 10 when the adhesive device 100 is attached to the skin, and the skin surface on which the drug-containing resin layer 10 is placed becomes more susceptible to softening due to moisture. In other words, moisture supplied to the skin surface from the adhesive surface 10A of the drug-containing resin layer 10 is less likely to escape from the base material 40 and more likely to remain between the drug-containing resin layer 10 and the skin, making the skin surface covered by the drug-containing resin layer 10 more susceptible to softening. In this case, a support 30 does not need to be provided on the underside of the drug-containing resin layer 10.

[0090] When the adhesive device 100 is used by attaching the drug-containing resin layer 10 to the skin together with the base material 40, it is preferable that the first surface 40A of the base material 40 has an adhesive portion in the first region 41 and a non-adhesive portion in the second region 42. It is also preferable to separate the first region 41 from the second region 42 and attach the adhesive device 100 to the skin. This allows the moisture-retaining portion 20 to be separated and the drug-containing resin layer 10 to be attached to the skin together with the base material 40. Therefore, in this case, it is preferable that the base material 40 has perforations formed in the planned fold portion 44 or fold line 45.

[0091] Even if the adhesive device 100 is used by peeling the drug-containing resin layer 10 from the base material 40 and attaching it to the skin, the base material 40 may have perforations formed in the planned folding portion 44 or folding line 45. The adhesive device 100 configured in this way can be used by separating the base material 40 at the perforations of the planned folding portion 44 or folding line 45 to separate the first region 41 from the second region 42, placing the drug-containing resin layer 10 on the skin together with the first region 41 of the base material 40 and attaching the drug-containing resin layer 10 to the skin, and then peeling the first region 41 of the base material 40 from the drug-containing resin layer 10. This makes it possible to attach the adhesive device 100 to the skin without touching the drug-containing resin layer 10.

[0092] The drug-containing resin layer 10 is preferably provided protruding from the first surface 40A of the base material 40. That is, the adhesive surface 10A of the drug-containing resin layer 10 is preferably located above the first surface 40A of the base material 40 in the thickness direction. This makes it easier to peel the drug-containing resin layer 10 from the base material 40 when peeling it off and applying it to the skin. When the drug-containing resin layer 10 is applied to the skin together with the base material 40, it is easier to improve the adhesion of the drug-containing resin layer 10 to the skin.

[0093] An adhesive device 100 that satisfies each of the above-described conditions, either individually or in appropriate combination, regarding the water content of the laminate 11, the water contact angle of the second surface 30B of the support 30, the increase in dW per unit area of ​​the laminate sample 11S after immersion, and the surface roughness Ra and Rz of the adhesive surface 10A, may further include a water-permeable sheet 21 as described below. Each of the above conditions may also be evaluated for the drug-containing resin layer 10 or the laminate 11 in a state where the water-permeable sheet 21 has been peeled off.

[0094] Next, a configuration in which the adhesive device 100 has a water-permeable sheet 21 will be described. As shown in Figure 11, it is preferable that the adhesive device 100 has a hydrophobic region on the adhesive surface 10A and a water-permeable sheet 21 that is peelably bonded to the adhesive surface 10A. The adhesive device 100 is used by being attached to the skin and is a device that can deliver drugs transdermally. The adhesive device 100 is used by first attaching the moisture held in the moisture-retaining part 20 to the adhesive surface 10A of the drug-containing resin layer 10, and then attaching the adhesive surface 10A of the drug-containing resin layer 10 to the skin.

[0095] When the adhesive device 100 is used as described above, moisture adhering to the adhesive surface 10A of the drug-containing resin layer 10 adheres to the skin surface, making the skin surface covered by the drug-containing resin layer 10 more susceptible to becoming soft and pliable due to the moisture. This enhances the adhesion of the drug-containing resin layer 10 to the skin surface and improves the penetration of the drug from the drug-containing resin layer 10 into the skin. Furthermore, since the adhesive surface 10A of the drug-containing resin layer 10 has a hydrophobic region, when moisture adheres to the adhesive surface 10A of the drug-containing resin layer 10 and it is applied to the skin, it becomes easier to release the drug from the drug-containing resin layer 10. For example, if the entire adhesive surface 10A of the drug-containing resin layer 10 is a hydrophilic region, even if moisture is applied to the adhesive surface 10A of the drug-containing resin layer 10, the drug will not be sufficiently distributed to the moisture and will tend to remain in the drug-containing resin layer 10. However, if the adhesive surface 10A of the drug-containing resin layer 10 has a hydrophobic region, the drug contained in the drug-containing resin layer 10 will more easily migrate from the drug-containing resin layer 10 to the moisture applied to the adhesive surface 10A. The drug released from the drug-containing resin layer 10 will not return to the drug-containing resin layer 10 but will more easily penetrate the skin along with the moisture.

[0096] However, when moisture is applied to the adhesive surface 10A of the drug-containing resin layer 10 formed as described above, the adhesive surface 10A has a hydrophobic region, so even if moisture is supplied to the adhesive surface 10A from the moisture-retaining part 20, the moisture is repelled on the adhesive surface 10A, making it difficult for moisture to remain on the adhesive surface 10A. Therefore, it is preferable that the adhesive device 100 is provided with a water-permeable sheet 21 that is peelably bonded to the adhesive surface 10A of the drug-containing resin layer 10. When using the adhesive device 100, the water-permeable sheet 21 is brought into contact with the moisture-retaining part 20, allowing the water-permeable sheet 21 to retain moisture, making it easier for moisture to remain on the adhesive surface 10A of the drug-containing resin layer 10. After that, the water-permeable sheet 21 is peeled off from the adhesive surface 10A of the drug-containing resin layer 10, thereby attaching the adhesive surface 10A of the drug-containing resin layer 10 to the skin. The adhesive device 100 includes a water-permeable sheet 21, which makes it easier to attach the drug-containing resin layer 10 to the skin by allowing moisture to adhere to the adhesive surface 10A.

[0097] Therefore, it is preferable that the adhesive device 100 is used by bringing the water-permeable sheet 21 into contact with the moisture-retaining portion 20 to wet the water-permeable sheet 21.

[0098] The adhesive surface 10A of the drug-containing resin layer 10 may be entirely hydrophobic, or it may have a hydrophilic region in part. It is preferable that a wide area of ​​the adhesive surface 10A of the drug-containing resin layer 10 is hydrophobic; for example, it is preferable that 50% or more of the adhesive surface 10A of the drug-containing resin layer 10 is hydrophobic, more preferably 70% or more, even more preferably 80% or more, and even more preferably 90% or more. The area of ​​the adhesive surface 10A of the drug-containing resin layer 10 other than the hydrophobic region can be called the hydrophilic region. The water contact angle in the hydrophilic region is preferably less than 80°, and may be 75° or less, 70° or less, 60° or less, 50° or less, or 40° or less. If the adhesive surface 10A of the drug-containing resin layer 10 has both hydrophobic and hydrophilic regions, it is preferable to cut out each region and measure the water contact angle.

[0099] The permeable sheet 21 is not particularly limited as long as it is a sheet that can pass moisture through. Examples of permeable sheet 21 include fabric materials such as nonwoven fabrics, woven fabrics, knitted fabrics, and any sheet material having openings. Among these, the permeable sheet 21 is preferably a perforated sheet or a mesh sheet.

[0100] The perforated sheet is preferably a sheet material with openings formed therein. The material of the perforated sheet is not particularly limited and can be appropriately selected according to the purpose. For example, paper such as glassine paper; resin films made from polyethylene, polyolefin (e.g., polyethylene, polypropylene), polyester (e.g., polyethylene terephthalate), polystyrene, etc.; aluminum foil or aluminum film; foamed resin films such as foamed polyethylene film and foamed polypropylene film can be used. These may be used individually or in combination. The perforated sheet may also be treated with silicone processing, fluororesin processing, embossing, hydrophilic processing, hydrophobic processing, etc. The shape of the opening of the perforated sheet is not particularly limited and can be circular, elliptical, oblong, polygonal, irregular, etc. The size of the opening of the perforated sheet is preferably, for example, 0.5 mm to 10 mm in terms of the equivalent diameter of a circle.

[0101] A mesh sheet is a sheet in which wires are arranged in a mesh pattern, and at the intersections of the wires arranged in the mesh pattern, the wires may or may not be joined to each other. The wires may be joined to each other by adhesive or by welding. Yarn is preferably used as the wire. The yarn may be spun yarn or filament yarn, and the filament yarn may be monofilament yarn or multifilament yarn. The size of the mesh opening of the mesh sheet is preferably, for example, 0.05 mm to 3 mm in terms of the equivalent diameter of a circle.

[0102] The opening ratio of the perforated sheet and the mesh sheet is preferably 10% to 40%, and more preferably 15% to 30%. The opening ratio is determined by measuring the area of ​​each opening formed in the perforated sheet or mesh sheet when the perforated sheet or mesh sheet is placed on a flat surface, and dividing this by the area enclosed by the outer edge of the perforated sheet or mesh sheet.

[0103] The permeable sheet 21 preferably covers 50% or more of the area of ​​the adhesive surface 10A of the drug-containing resin layer 10, more preferably 70% or more, even more preferably 80% or more, and even more preferably 90% or more. The permeable sheet 21 may also cover 100% of the area of ​​the adhesive surface 10A. This allows a wider area of ​​the adhesive surface 10A of the drug-containing resin layer 10 to be wetted with moisture when the permeable sheet 21 is brought into contact with the moisture-retaining part 20. In Figures 11 and 12, the permeable sheet 21 is formed to the same size as the adhesive surface 10A of the drug-containing resin layer 10.

[0104] As shown in Figure 13, it is preferable that the water-permeable sheet 21 extends beyond the adhesive surface 10A. Figure 13 shows a cross-sectional view of another embodiment of the adhesive device 100. In Figure 13, in a plan view of the adhesive device 100, the water-permeable sheet 21 extends beyond the adhesive surface 10A of the drug-containing resin layer 10. This makes it easier to peel the water-permeable sheet 21 from the adhesive surface 10A of the drug-containing resin layer 10 after the water-permeable sheet 21 has been brought into contact with the moisture-retaining portion 20 and has retained moisture in the water-permeable sheet 21.

[0105] When attaching the adhesive device 100 to the skin, it is desirable that as much moisture as possible, supplied from the moisture-retaining section 20 and retained in the permeable sheet 21, adheres to the skin surface. From this perspective, when attaching the adhesive device 100 to the skin, it is desirable to have the permeable sheet 21 retain moisture and to attach the permeable sheet 21 to the adhesive surface 10A of the drug-containing resin layer 10, then to face the adhesive surface 10A of the drug-containing resin layer 10 toward the skin, and in this state, to peel the permeable sheet 21 from the adhesive surface 10A. At this time, if the permeable sheet 21 extends beyond the adhesive surface 10A, it becomes easier to peel the permeable sheet 21 from the adhesive surface 10A while the adhesive surface 10A of the drug-containing resin layer 10 is facing the skin. Subsequently, by attaching the adhesive surface 10A of the drug-containing resin layer 10 to the skin, more moisture can be created between the drug-containing resin layer 10 and the skin surface, making the skin surface covered by the drug-containing resin layer 10 more supple and soft.

[0106] As shown in Figure 14, it is also preferable that the water-permeable sheet 21 has a tab 24 that is folded back on the side opposite to the adhesive surface 10A. Figure 14 shows a cross-sectional view of another embodiment of the adhesive device 100. If the water-permeable sheet 21 has a tab 24, it becomes easier to peel the water-permeable sheet 21 from the adhesive surface 10A of the drug-containing resin layer 10. For example, even if the water-permeable sheet 21 does not protrude from the adhesive surface 10A, it becomes easier to peel the water-permeable sheet 21 from the adhesive surface 10A.

[0107] As shown in Figure 15, two or more water-permeable sheets 21 may be provided on the adhesive surface 10A of the drug-containing resin layer 10. That is, the water-permeable sheet 21 may include a first water-permeable sheet 22 and a second water-permeable sheet 23. Figure 15 shows a cross-sectional view of another embodiment of the adhesive device 100. In this case, for example, after the first water-permeable sheet 22 and the second water-permeable sheet 23 have been allowed to retain moisture, one of the first water-permeable sheet 22 and the second water-permeable sheet 23 is peeled off from the adhesive surface 10A to attach a portion of the adhesive surface 10A of the drug-containing resin layer 10 to the skin. In that state, the other of the first water-permeable sheet 22 and the second water-permeable sheet 23 is then peeled off from the adhesive surface 10A to attach the remaining portion of the adhesive surface 10A of the drug-containing resin layer 10 to the skin. By attaching the drug-containing resin layer 10 to the skin in this way, it becomes easier to create a larger amount of moisture between the drug-containing resin layer 10 and the skin surface.

[0108] Preferably, the first water-permeable sheet 22 and the second water-permeable sheet 23 are laminated on the side of the first water-permeable sheet 22 opposite to the adhesive surface 10A, with the first water-permeable sheet 22 being peelably bonded to the adhesive surface 10A and the second water-permeable sheet 23 being peelably bonded to the adhesive surface 10A. With the first water-permeable sheet 22 and the second water-permeable sheet 23 provided in this way, it becomes easier to attach the adhesive device 100 to the skin and easier to allow a larger amount of moisture to adhere to the skin surface. In this case, it is preferable that the first water-permeable sheet 22 has a tab that is folded back on the side opposite to the adhesive surface 10A, which makes it easier to peel the first water-permeable sheet 22 from the adhesive surface 10A. Preferably, the tab portion of the first water-permeable sheet 22 is covered by the second water-permeable sheet 23, which makes it easier to peel off only the second water-permeable sheet 23 from the adhesive surface 10A without having to grasp the tab portion of the first water-permeable sheet 22. In this case, the second water-permeable sheet 23 may also have a tab portion that is folded back on the side opposite to the adhesive surface 10A.

[0109] As shown in Figures 11 to 15, when the adhesive device 100 has a water-permeable sheet 21, it is preferable that the base material 40 is folded back between the drug-containing resin layer 10 and the moisture-retaining portion 20 with the first surface 40A facing inward, so that the water-permeable sheet 21 overlaps the moisture-retaining portion 20. Specifically, it is preferable that the base material 40 has a planned fold portion 44 at the boundary between the first region 41 and the second region 42, and that the drug-containing resin layer 10 and the moisture-retaining portion 20 are arranged on the base material 40 so that the water-permeable sheet 21 overlaps the moisture-retaining portion 20 by folding the base material 40 at the planned fold portion 44 with the first surface 40A facing inward. In this configuration, before use of the adhesive device 100, the base material 40 is not folded back at the planned fold portion 44. When using the adhesive device 100, by folding the base material 40 with the first surface 40A facing inward at the planned folding portion 44, the permeable sheet 21 provided on the adhesive surface 10A of the drug-containing resin layer 10 can be overlapped with the moisture-retaining portion 20, as shown in Figure 16, and moisture can be attached to the permeable sheet 21. Figure 16 shows the adhesive device 100 shown in Figure 11 with the base material 40 folded at the planned folding portion 44. In this form of adhesive device 100, by folding the base material 40 and overlapping the permeable sheet 21 with the moisture-retaining portion 20, moisture can be easily supplied to the permeable sheet 21 provided on the adhesive surface 10A of the drug-containing resin layer 10.

[0110] The portion 44 of the base material 40 intended to be folded may or may not have a fold formed in advance. In the former case, it is preferable that a fold line is formed on the first surface 40A of the base material 40 in the portion 44 intended to be folded. In the latter case, the portion 44 of the base material 40 may be provided with a mark indicating the position where the fold will be formed, or the base material 40 may be formed with a thinner thickness in the portion 44 intended to be folded, or the base material 40 may be formed with lower rigidity in the portion 44 intended to be folded, or perforations may be formed on the portion 44 intended to be folded of the base material 40.

[0111] Preferably, the base material 40 has a valley fold line formed on its first surface 40A as a planned folding section 44. The valley fold line of the base material 40 may be a groove formed on the first surface 40A of the base material 40. By forming a valley fold line on the first surface 40A of the base material 40, it becomes easier to fold the base material 40 along the valley fold line when the first surface 40A is folded inward, making it easier to accurately overlap the moisture-retaining section 20 with the water-permeable sheet 21 provided on the adhesive surface 10A of the drug-containing resin layer 10.

[0112] It is also preferable that the base material 40 has perforations formed as a portion 44 for folding. In this case as well, when the base material 40 is folded with the first surface 40A facing inward, it becomes easier to fold it along the perforations, and it becomes easier to accurately overlap the moisture-retaining portion 20 with the permeable sheet 21 provided on the adhesive surface 10A of the drug-containing resin layer 10.

[0113] In another embodiment, the adhesive device 100 may have a base material 40 that is pre-folded, as shown in Figure 17. That is, the base material 40 is folded with the first surface 40A facing inward, and it is also preferable that the water-permeable sheet 21 and the moisture-retaining portion 20 are arranged on the base material 40 so that they overlap each other. In this embodiment, before use of the adhesive device 100, the base material 40 is folded along a fold line 45 between the drug-containing resin layer 10 and the moisture-retaining portion 20. The fold line 45 is formed at the boundary between the first region 41 and the second region 42 of the base material 40, and the base material 40 is arranged so that the water-permeable sheet 21 and the moisture-retaining portion 20 overlap each other in a plan view of the adhesive device 100. This embodiment of the adhesive device 100 can also easily supply moisture to the water-permeable sheet 21 provided on the adhesive surface 10A of the drug-containing resin layer 10.

[0114] The base material 40 may be separable into a first region 41 and a second region 42 at a planned fold portion 44 or a fold line 45. For example, the base material 40 can be made separable into a first region 41 and a second region 42 by forming the planned fold portion 44 or fold line 45 from perforations.

[0115] As shown in Figures 19 and 20, the adhesive device 100 further includes a release sheet 60, and it is preferable that the release sheet 60 is provided so as to cover at least one of the water-permeable sheet 21 and the moisture-retaining portion 20. Figures 19 and 20 show cross-sectional views of other embodiments of the adhesive device 100, with Figure 19 showing an embodiment in which the adhesive device 1 shown in Figure 11 is further provided with a release sheet 60, and Figure 20 showing an embodiment in which the adhesive device 100 shown in Figure 17 is further provided with a release sheet 60.

[0116] If the release sheet 60 is provided so as to cover the moisture-retaining portion 20, it is possible to prevent moisture from leaking from the moisture-retaining portion 20 before use of the adhesive device 100. If the release sheet 60 is provided so as to cover the water-permeable sheet 21, it is possible to prevent the water-permeable sheet 21 from unintentionally peeling off from the adhesive surface 10A of the drug-containing resin layer 10 before use of the adhesive device 100. When using the adhesive device 100, the release sheet 60 is peeled off to expose the water-permeable sheet 21 provided on the adhesive surface 10A of the drug-containing resin layer 10, and the water-permeable sheet 21 is brought into contact with the moisture-retaining portion 20.

[0117] When the adhesive device 100 includes a base material 40, it is preferable that the release sheet 60 is provided on the first surface 40A side of the base material 40. It is preferable that the release sheet 60 is laminated on the base material 40 so as to cover at least one of the water-permeable sheet 21 and the moisture-retaining portion 20 on the first surface 40A side of the base material 40, and that the release sheet 60 is peelably bonded to the base material 40. When the release sheet 60 is provided so as to cover the moisture-retaining portion 20, it is preferable that the release sheet 60 is peelably bonded to the base material 40 so as to surround the moisture-retaining portion 20. The release sheet 60 may also be provided on the first surface 40A side of the base material 40, overlapping the entire base material 40.

[0118] In order for the release sheet 60 to be removably bonded to the base material 40, it is preferable that an adhesive layer is provided on the release sheet 60 or the base material 40, or that the release sheet 60 and the base material 40 are pressed together. The release sheet 60 and the base material 40 may also be heat-pressed together.

[0119] It is preferable that the release sheet 60 is not adhered to the water-permeable sheet 21. This prevents the water-permeable sheet 21 from peeling off the adhesive surface 10A of the drug-containing resin layer 10 when the release sheet 60 is removed.

[0120] As shown in Figure 20, if the base material 40 is folded along the fold line 45 between the drug-containing resin layer 10 and the moisture-retaining portion 20 before use of the adhesive device 100, it is preferable that the release sheet 60 is laminated on the first surface 40A of the base material 40 in the folded state. In this case, it is preferable that one side of the fold of the release sheet 60 is laminated on the first region 41 of the first surface 40A of the base material 40, and the other side of the fold of the release sheet 60 is laminated on the second region 42 of the first surface 40A of the base material 40. It is preferable that the fold of the release sheet 60 is positioned to overlap with the fold line 45 of the base material 40.

[0121] In the above case, it is preferable that a traction sheet is bonded to the inner surface of the folded release sheet 60, and that the traction sheet extends from the edge of the release sheet 60 opposite to the fold. By pulling the traction sheet while the base material 40 is folded at the fold between the drug-containing resin layer 10 and the moisture-retaining portion 20, the release sheet 60 can be pulled out from between the folded base material 40, and the water-permeable sheet 21 can be brought into contact with the moisture-retaining portion 20. This makes it possible to easily supply moisture to the water-permeable sheet 21 provided on the adhesive surface 10A of the drug-containing resin layer 10.

[0122] It is preferable that the size of the water-permeable sheet 21 is smaller than the size of the moisture-retaining portion 20. Specifically, in a plan view of the adhesive device 100, it is preferable that the size of the water-permeable sheet 21 is smaller than the size of the moisture-retaining portion 20. This makes it easier to bring the entire water-permeable sheet 21 into contact with the moisture-retaining portion 20 when the base material 40 is folded at the planned folding portion 44 or the folding line 45, and makes it easier to adhere moisture to a wide area of ​​the water-permeable sheet 21. More preferably, the size of the water-permeable sheet 21 and the drug-containing resin layer 10 are formed to be smaller than the size of the moisture-retaining portion 20.

[0123] It is preferable that the size of the water-permeable sheet 21 and the drug-containing resin layer 10 be smaller than the size of the recess 46 in the base material 40. Specifically, in a plan view of the adhesive device 100, it is preferable that the size of the water-permeable sheet 21 and the drug-containing resin layer 10 be smaller than the size of the recess 46. This allows the entire water-permeable sheet 21 to be placed inside the recess 46 when the base material 40 is folded back at the planned folding section 44 or the folding line 45, making it easier for more moisture to adhere to the water-permeable sheet 21.

[0124] The adhesive device 100 further includes a support 30 laminated on the side of the drug-containing resin layer 10 opposite to the adhesive surface 10A, and it is preferable that water adheres to the adhesive surface 10A of the drug-containing resin layer 10. It is preferable that this water is the moisture described above. The water adhering to the adhesive surface 10A may be droplet-shaped water 50a as shown in Figure 21, or layer-shaped water 50b as shown in Figure 22. Although the drug-containing resin layer 10 is hydrophobic, if a large amount of water adheres to it, it can adhere in layers due to the weight of the water. It is also preferable that the water adhering to the adhesive surface 10A adheres in layers. This makes it easier to retain a large amount of water on the adhesive surface 10A, thus making the above effects more achievable.

[0125] Furthermore, the presence of water on the adhesive surface 10A makes it less likely for the adhesive surface 10A to adhere firmly to the skin, thus making it easier to reapply. In addition, the adhesive properties of the adhesive surface 10A can be restored after the drug-containing water has penetrated the skin. This makes it easier to provide an adhesive device 100 that can be easily placed in the desired position and has improved drug absorption efficiency.

[0126] In a plan view from the adhesive surface 10A side, it is preferable that the total area of ​​the water-covered portion is 5% to 100% of the total area of ​​the adhesive surface 10A. More preferably, in a plan view from the adhesive surface 10A side, the total area of ​​the water-covered portion is 10% or more, even more preferably 30% or more, and even more preferably 50% or more. If water is present on the adhesive surface 10A within the above range, the above effects are more likely to be achieved. In a plan view from the adhesive surface 10A side, it is more preferable that the total area of ​​the water-covered portion is 90% or less, even more preferably 80% or less, and even more preferably 70% or less. If water is present on the adhesive surface 10A within the above range, it is possible to prevent water from leaking between the adhesive surface 10A and the skin when the adhesive surface 10A is applied to the skin.

[0127] The adhesive device 100 can be used by placing it on epithelial tissue. The epithelial tissue on which the adhesive device 100 is placed may be epithelial tissue of the skin or epithelial tissue of the mucous membrane, but it is preferably epithelial tissue of the skin. The adhesive device 100 is preferably placed on human epithelial tissue, but it may also be placed on epithelial tissue of animals other than humans, such as dogs, cats, horses, and cows.

[0128] This application claims the benefit of priority based on Japanese Patent Application No. 2025-52031, No. 2025-52030, No. 2025-52029, and No. 2025-52034, all filed on March 26, 2025. The entire contents of the specifications of Japanese Patent Application No. 2025-52031, Japanese Patent Application No. 2025-52030, Japanese Patent Application No. 2025-52029, and Japanese Patent Application No. 2025-52034, filed on 26 March 2025, are incorporated herein by reference.

[0129] 10: Drug-containing resin layer 10A: Adhesion surface 11: Laminate 20: Moisture-retaining part 21: Water-permeable sheet 22: First water-permeable sheet 23: Second water-permeable sheet 24: Grip part 30: Support 40: Substrate 41: First region 42: Second region 44: Planned folding part 45: Folding line 46: Recess 50a: Water droplets 50b: Layered water 60: Release sheet 100: Adhesion device

Claims

1. An adhesive device comprising a drug-containing resin layer having an adhesive surface and a moisture-retaining portion.

2. The adhesive device according to claim 1, comprising a laminate including a support having a first surface and a second surface opposite to the first surface, and the drug-containing resin layer laminated on the first surface side of the support, wherein the water content of the laminate, as measured by the Karl Fischer method in accordance with the Japanese Pharmacopoeia, is 0 ppm or more and 50,000 ppm or less by mass ratio.

3. The adhesive device according to claim 2, wherein when a 2 μL droplet of water is dropped onto the second surface of the support under conditions of 20°C and 50% RH, the water contact angle is 90 degrees or more.

4. The adhesive device has a laminate comprising a support having a first surface and a second surface opposite to the first surface, and the drug-containing resin layer laminated on the first surface side of the support, with an area A cm from the laminate. ２ The increase in weight per unit area of ​​the laminated sample W2 when the laminated sample is immersed in water for 10 seconds so that the drug-containing resin layer is submerged, then removed from the water and suspended vertically for 10 seconds, and then placed horizontally with the second surface facing downwards, relative to the weight W1 of the cut laminated sample, is dW [(W2 - W1) / A]. ２ 5mg / cm or more ２ The adhesive device according to claim 1, which is as follows:

5. The aforementioned increase dW is 0 mg / cm ２ 1mg / cm or more ２ The adhesive device according to claim 4, which is as follows:

6. The adhesive device according to claim 1, wherein the adhesive surface of the drug-containing resin layer has a portion A having an arithmetic mean roughness Ra of 5 μm or more and 15 μm or less.

7. The adhesive device according to claim 6, wherein the maximum height Rz of the portion A is 30 μm or more and 100 μm or less.

8. The adhesive device according to claim 1, wherein the adhesive surface has a hydrophobic region, and a water-permeable sheet is peelably bonded to the adhesive surface.

9. The adhesive device according to claim 8, wherein the adhesive device is used by bringing the permeable sheet into contact with the moisture-retaining portion to wet the permeable sheet.

10. The adhesive device according to claim 8, wherein the permeable sheet is a perforated sheet or a mesh sheet.

11. The adhesive device according to claim 8, wherein the permeable sheet covers an area of ​​50% or more of the adhesive surface.

12. The adhesive device according to claim 8, wherein the water-permeable sheet is provided extending beyond the adhesive surface.

13. The adhesive device according to claim 8, wherein the water-permeable sheet has a tab that is folded back on the side opposite to the adhesive surface.

14. The adhesive device according to claim 8, wherein the permeable sheet comprises a first permeable sheet and a second permeable sheet, the first permeable sheet being peelably bonded to the adhesive surface, and the second permeable sheet being peelably bonded to the adhesive surface and laminated on the surface of the first permeable sheet opposite to the adhesive surface.

15. The adhesive device according to claim 8, wherein the adhesive device comprises a laminate including a support having a first surface and a second surface opposite to the first surface, and the drug-containing resin layer laminated on the first surface side of the support, and the water content of the laminate, as measured by the Karl Fischer method in accordance with the Japanese Pharmacopoeia, is 0 ppm or more and 50,000 ppm or less by mass ratio.

16. The adhesive device according to claim 15, wherein the water contact angle is 90 degrees or more when a 2 μL water droplet is dropped onto the second surface of the support in an environment of 20°C and 50% RH.

17. The adhesive device has a laminate comprising a support having a first surface and a second surface opposite to the first surface, and the drug-containing resin layer laminated on the first surface side of the support, with an area A cm from the laminate. ２ The increase in weight per unit area of ​​the laminated sample W2 when the laminated sample is immersed in water for 10 seconds so that the drug-containing resin layer is submerged, then removed from the water and suspended vertically for 10 seconds, and then placed horizontally with the second surface facing downwards, relative to the weight W1 of the cut laminated sample, is dW [(W2 - W1) / A]. ２ 5mg / cm or more ２ The adhesive device according to claim 8, which is as follows:

18. The increased dW is 0 mg / cm ２ or more and 1 mg / cm ２ or less according to claim 17. The patch device according to claim 17.

19. The adhesive device according to claim 8, wherein the adhesive surface of the drug-containing resin layer has a portion A having an arithmetic mean roughness Ra of 5 μm or more and 15 μm or less.

20. The adhesive device according to claim 19, wherein the maximum height Rz of the portion A is 30 μm or more and 100 μm or less.

21. The adhesive device according to any one of claims 1 to 20, wherein the drug-containing resin layer is adhesive.

22. The adhesive device according to any one of claims 1 to 20, wherein the moisture-retaining portion includes a porous body that retains moisture or a fiber aggregate that retains moisture.

23. The adhesive device according to any one of claims 1 to 20, further comprising a support laminated on the surface of the drug-containing resin layer opposite to the adhesive surface, wherein water is adhering to the adhesive surface of the drug-containing resin layer.

24. The adhesive device according to claim 23, wherein, in a plan view from the adhesive surface side, the total area of ​​the portion to which water is attached is 5% or more and 100% or less of the area of ​​the adhesive surface.

Images